Currently, there are two U.S Food and Drug Administration-approved biomarkers that predict the efficacy of ICI treatment: (1) Expression of PD-L1 in tumor tissues; and (2) the presence of microsatellite-instability–high (MSI-H)/DNA mismatch repair–deficient (dMMR) in tumor tissues. Here, CD274 is linked to neoplasm.